Mixed Connective Tissue Disease

On this page

MCTD Introduction - The Great Overlap

  • MCTD: A distinct systemic autoimmune rheumatic disease, often termed an "overlap syndrome."
  • Key characteristic: Combines clinical features typically seen in:
    • Systemic Lupus Erythematosus (SLE)
    • Systemic Sclerosis (SSc)
    • Polymyositis (PM) and/or Dermatomyositis (DM)
  • Initial presentation can be as Undifferentiated Connective Tissue Disease (UCTD).
  • Disease course: May remain stable MCTD or evolve into a more defined CTD over time.
  • Serological hallmark: Presence of high titers of antibodies to U1 ribonucleoprotein (anti-U1 RNP).

    ⭐ MCTD is characterized by high titers of anti-U1 RNP antibodies. oka

MCTD Pathophysiology - Immune System Mix-up

  • Immune Dysregulation: Central defect; involves hyperactive T-cells & B-cells, leading to loss of self-tolerance.
  • Autoantibody Production: Key feature is high-titer anti-U1-RNP antibodies.
    • These antibodies recognize specific proteins (70kD, A, C) on U1 small nuclear ribonucleoprotein (snRNP) particles, crucial for mRNA splicing.
  • Mechanism of Damage: Not fully elucidated but involves:
    • Immune complex deposition.
    • Complement activation.
    • Endothelial cell injury & T-cell mediated cytotoxicity.
  • Result: Inflammation & damage in various connective tissues.

⭐ Anti-U1-RNP antibodies target the 70-kD, A, and C proteins of the U1 small nuclear ribonucleoprotein particle.

RNP Self Antigen-driven Autoimmunity Model

MCTD Clinical Features - A Symptom Medley

MCTD Symptoms: Raynaud's, swollen fingers, rashes, pain

  • Hallmarks (Often Initial):
    • Raynaud's phenomenon: Vasospasm of digits; nearly 100% prevalence.
    • Swollen hands/Puffy fingers: Diffuse swelling ("sausage digits"), may evolve to sclerodactyly.
  • Musculoskeletal:
    • Arthralgia/Polyarthritis: Symmetric, non-erosive; Jaccoud's arthropathy (deforming but reducible) possible.
    • Inflammatory Myositis: Proximal muscle weakness, tenderness; elevated CK.
  • Systemic Manifestations:
    • Esophageal dysmotility: Dysphagia for solids/liquids, reflux.
    • Pulmonary: Interstitial Lung Disease (ILD), Pulmonary Arterial Hypertension (PAH) - significant morbidity/mortality.
    • Cardiac: Pericarditis most common; myocarditis, conduction defects.
    • Renal: Mild glomerulonephritis (membranous nephropathy commonest).
    • Neurologic: Trigeminal neuropathy is the most frequent CNS finding.
  • Skin (Overlap Features):
    • SLE-like: Malar rash, photosensitivity.
    • SSc-like: Sclerodactyly, calcinosis cutis.
    • DM-like: Gottron's papules (less common).

⭐ Raynaud's phenomenon is an almost universal presenting feature in MCTD.

MCTD Diagnosis - Pinpointing the Puzzle

  • Diagnosis combines clinical criteria and specific serology.
    • Commonly used criteria: Alarcon-Segovia, Kasukawa, Sharp.
  • Clinical Presentation:
    • Requires ≥2 CTD features (SLE, SSc, PM/DM).
    • Key manifestations: Raynaud's phenomenon, swollen hands/puffy fingers, arthralgia/arthritis, myositis, esophageal dysmotility, acrosclerosis.
  • Serological Hallmark:
    • Essential: High-titer anti-U1 RNP antibodies (specifically U1 small nuclear ribonucleoprotein).
    • ANA: Typically high-titer, speckled pattern.

⭐ High-titer anti-U1 RNP is essential for diagnosis, often in the absence of other specific autoantibodies like anti-dsDNA or anti-Scl-70.

  • Supportive Serology:
    • Other disease-specific autoantibodies (e.g., anti-dsDNA, anti-Sm, anti-Scl-70, anti-centromere, anti-Jo-1) typically absent or in low titers.

MCTD Management - Taming the Tempest

  • Goal: Symptom control & organ protection.
  • Mild disease (arthralgia, myalgia, rash):
    • NSAIDs, Hydroxychloroquine (HCQ)
    • Low-dose corticosteroids
  • Moderate-Severe disease (organ involvement):
    • High-dose corticosteroids
    • Immunosuppressants (Methotrexate, Azathioprine, Mycophenolate mofetil)
    • Biologics (e.g., Rituximab) for refractory cases.
  • Raynaud's: Calcium channel blockers, lifestyle changes.
  • Pulmonary Hypertension: Vasodilators (PDE5-inhibitors, ERAs, prostanoids).

⭐ Pulmonary hypertension is a major cause of mortality in MCTD.

  • Regular follow-up is crucial for monitoring disease activity and complications.

High‑Yield Points - ⚡ Biggest Takeaways

  • MCTD is a distinct overlap syndrome with features of SLE, systemic sclerosis, and polymyositis/dermatomyositis.
  • Serological hallmark: Presence of high-titer anti-U1 RNP antibodies.
  • Frequent early manifestations: Raynaud's phenomenon, swollen hands or puffy fingers, and arthralgias.
  • Pulmonary hypertension is a critical complication and a leading cause of mortality.
  • Other significant involvements include arthritis, myositis, esophageal dysmotility, and interstitial lung disease.
  • Often referred to as Sharp's syndrome.

Practice Questions: Mixed Connective Tissue Disease

Test your understanding with these related questions

A 34-year-old woman has Raynaud's phenomenon associated with systemic sclerosis (scleroderma). Which of the following is the most appropriate management for this condition?

1 of 5

Flashcards: Mixed Connective Tissue Disease

1/8

Limited scleroderma is characterized by limited skin involvement confined to _____ and face

TAP TO REVEAL ANSWER

Limited scleroderma is characterized by limited skin involvement confined to _____ and face

fingers

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial